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Background: Currently, there are no consistently effective chemotherapies for recurrent and inoperable
meningiomas. Recently, cucurbitacin I (JSI-124), a naturally occurring tetracyclic triterpenoid compound used as folk
medicines has been found to have cytoxic and anti-proliferative properties in several malignancies thru inhibition of
activator of transcription (STAT3) activation. Previously, we have found STAT3 to be activated in meningiomas,
particularly higher grade tumors.
Methods: Primary leptomeningeal cultures were established from 17, 20 and 22 week human fetuses and
meningioma cell cultures were established from 6 World Health Organization (WHO) grade I or II meningiomas.
Cells were treated with cerebrospinal fluid from patients without neurologic disease. The effects of cucurbitacin I on
cerebrospinal fluid stimulation of meningioma cell DNA synthesis phosphorylation/activation of JAK1, STAT3,
pMEK1/2, p44/42MAPK, Akt, mTOR, Rb and caspase 3 activation were analyzed in human leptomeningeal and
meningioma cells.
Results: Cerebrospinal fluid significantly stimulated DNA synthesis in leptomeningeal cells. Co-administration of
cucurbitacin I (250 nM) produces a significant blockade of this effect. Cucurbitacin I alone also produced a
significant reduction in basal DNA synthesis. In grade I and II meningiomas, cerebrospinal fluid also significantly
stimulated DNA synthesis. Co-administration of cucurbitacin I (250 nM) blocked this effect.
In the leptomeningeal cultures, cerebrospinal fluid stimulated STAT3 phosphorylation but not p44/42MAPK, Akt or
mTOR. Cucurbitacin I had no effect on basal STAT3 phosphorylation but co-administration with cerebrospinal fluid
blocked cerebrospinal fluid stimulation of STAT3 phosphorylation in each. In the grade I meningiomas, cerebrospinal
fluid stimulated phosphorylation of STAT3 and decreased MEK1/2 and cucurbitacin I had no effect on basal STAT3,
p44/42MAPK, Akt, JAK1, mTOR, or Rb phosphorylation. In the grade II meningiomas, cerebrospinal fluid stimulated
STAT3 phosphorylation in all and reduced phosphorylation of MEK1/2 in all and p44/42MAPK in one. Cucurbitacin I
had no effect on basal phosphorylation of STAT3 but reduced phorphorylated p44/42 MAPK in 2 grade II meningioma
cells lines.
Conclusions: These studies raise the possibility that cucurbitacin I might have value as an adjunct chemotherapy.
Additional studies are warranted to evaluate the effects of cucurbitacin I on meningiomas in vivo.* Correspondence: mahlon_johnson@urmc.rochester.edu
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Figure 1 Structure of cucurbitacin I. Cucurbitacin I is a tetracyclic
triterpene compound that has been used in Chinese, Indian and
South American folk medicine.
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The lack of effective chemotherapies compromises
management of recurrent or inoperable meningiomas
[1,2]. Approximately 12% of intracranial world health
organization (WHO) grade I meningiomas recur within
5 years of gross total resection [3,4]. Intracranial, WHO
grade II, tumors may recur with a frequency as high as
29-41% within 5 years after gross total resection [5,6].
Recurrence rates of skull base meningiomas are even
higher [7,8]. In these cases effective chemotherapies
have not been established and recent promising treatments
have proven suboptimal [9-12]. In most recurrences, man-
agement includes radiotherapy but this may be less effective
[13] than in cases of de novo meningiomas where radiation
can produce a 93% control at 5 years and 87% at 15 years
[14]. In a recent study of Gamma Knife-treated skull
base meningiomas, followed for up to 103 months, 33%
exhibited variable regression, 64% were stabilized and
6% showed progression [15]. However, stereotactic radio-
surgery produced only a 49% progression free survival in
atypical, WHO grade II meningiomas and is ineffective
in treatment of anaplastic meningiomas [15]. Moreover in
some studies, radiotherapy as an initial treatment was less
effective in large meningiomas greater than 5 cm3 [16].
Meningioma growth is regulated by complex interactions
between multiple mitogenic/anti-apoptotic signaling path-
ways [17]. Previously, we have found that several of these
pathways such as the MAPK kinase kinase-MAPK kinase-
mitogen activated protein kinase (Raf-1-MEK-1-MAPK)
pathway, phosphoinositide 3 kinase-protein kinase B/
Akt-proline rich-Akt substrate 40-mTOR (PI3K-PKB/
Akt-PRAS40-mTOR) pathway and phospholipase C-gamma
pathways are activated in WHO grade I meningiomas
[18-20]. The janus tyrosine kinase (JAK)-signal transducer
and activator of transcription (STAT3) pathway, and/or
STAT3 might also be involved [21-24]. These pathways
may be activated by autocrine or paracrine growth factor/
cytokine stimulation of meningioma cells rather than
constitutive activation of growth factor receptors or signal
transduction pathways [16,23]. Autocrine production of
many mitogenic cytokines and their presence in the cere-
brospinal fluid have been established [16,17,23,25].
Cucurbitacins are a family of naturally occurring tetracyc-
lic triterpenoid compounds that have been used as folk
medicines in China, India, Peru and Brazil for centuries
[26-29] (Figure 1). Six forms have been recognized. Cucur-
bitacin I, (JSI-124) [26] has recently been found to have
cytoxic and anti-proliferative properties in adenocarcinoma
cells [29] nasopharyngeal carcinoma cells and xenographs
[30], glioblastomas [31] anaplastic large cell lymphoma
[32] and non small cell carcinoma [33]. Initial studies
suggested that this was largely thru inhibition of the janus
kinase-3/signal trasnducer and activator of transcription-3
(JAK/STAT3) activation [26]. Cucurbitacin may also inhibittumor cell invasion [30] and has antiinflammatory prop-
erties [34,35].
Previously we have found that cerebrospinal fluid stimu-
lation of leptomeningeal and meningioma cell proliferation
is associated, in part, with activation of STAT3. In search
of a STAT3 inhibitor, we tested cucrbitacin I on STAT3 ac-
tivation in one leptomeningeal and meningioma culture
[23]. In the present study, to characterize cucurbitacin I,
we evaluated its effects on proliferation and growth regula-
tory pathways in numerous human leptomeningeal, grade
I and II meningioma cell cultures. To mimic the in vivo
milieu, we stimulated cells with cerebrospinal fluid from
patients found to have no neurological disease and platelet
derived growth factor BB (PDGF-BB), a known mitogen
for meningioma cells [19,20,23].
Methods
Human leptomeningeal and meningioma cell cultures
Primary leptomeningeal cultures were established from
de-identified postmortem leptomeninges from 17, 20
and 22 week human fetuses with University of Rochester
Institutional Review Board approval and postmotrm excep-
tion but prior autopsy/surgical maternal consent for use of
the tissue. Remnant, excess, discarded tissue/meningioma
cells were also collected (mean age 61 years; 4 females) with
University of Rochester Institutional Review Board approval
and surgical consent for use of tissue. M1-M3 were
WHO grade I meningothelial meningiomas from the
clivus, sphenoid wing or frontal lobe and all had detectable
Merlin protein. M4-M6 included a WHO grade II menin-
gothelial, transitional and microcystic meningioma from
the frontal lobe and the 2 analyzed also had detectable
Merlin protein. These cells were maintained in DMEM
with 10% fetal bovine serum (FBS) which is insufficient for
normal glia and endothelial cell survival and proliferation.
The cells used were screened for features of leptomenin-
geal and meningioma cells following procedures described
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epithelial membrane antigen (EMA) [36]. For experi-
ments, only early passage i.e. passage 2 to 5 were used
on meningioma cell cultures that showed EMA and vari-
able desmoplakin immunoreactivity by immunocytochem-
istry and Merlin protein [37,38]. For immunocytochemical
characterization, meningioma cell cultures were plated onto
2 well microscope slides (Nalgene NUNC Int., Rochester,
NY) for 1 day in DMEM with 10% FBS then fixed in
formalin. Immunocytochemistry was performed using
a mouse monoclonal antibody against epithelial membrane
antigen (EMA, prediluted) (DAKO, Carpenteria, CA)
and anti-desmoplakin (1:200; Abcam Inc., Cambridge
MA) using the streptavidin-biotin-horseradish peroxidase
method. The presence or loss of Neurofibromatosis-2 gene
product Merlin was assessed by western blot (data not
shown, 37, 38).
Human cerebrospinal fluid from patients without
neurologic disease
Remnant, discarded lumbar cerebrospinal fluid was
retrieved from samples collected at the University of
Rochester Medical Center (Rochester, NY) and sent to
the Dept. of Pathology for analysis between March,
2009 and September, 2012. As discarded remnant tissue, it
was exempted by the University of Rochester Institutional
review board from patient consent forms beyond standard
patient consent forms for tissue use. Samples from pa-
tients found to be free of neurological disease that had cy-
topathology analysis showing no erythrocytes or increased
lymphocytes and normal indices were classified as “nor-
mal”. In patients who had cerebrospinal fluid collected as
part of staging protocol for a peripheral lymphoma, only
cerebrospinal fluid from those with no cells by cytology
and no neurologic disease were used. Due to limited vol-
ume, in some cases multiple samples were combined as
pools to achieve some uniformity and enough volume to
treat large numbers of cells in T75 flasks. Samples were
initially frozen at −17°C then stored at −80°C.
Effects of cucurbitacin I on cerebrospinal fluid stimulation
of meningioma cell DNA synthesis
Confluent cells from human 17, 20 and 22 week fetal
leptomeninges (L1-L3), 3 WHO grade I (M1 -M3) and 3
WHO grade II (M4- M6) were plated in 96 well plates,
serum deprived overnight then treated with serum free
DMEM, undiluted cerebrospinal fluid, DMEM and
cucurbitacin I (250 nM) or cerebrospinal fluid with cucurbi-
tacin (250 nM, Calbiochem, CA) for 72 hrs. This dose was
chosen based on the dose response curves and previous
literature using doses as high as 10 uM [26] or lower
[30,31]. Cells were subsequently analyzed in 6 repli-
cates by CyQUANT Cell Proliferation assay (Invitrogen,
Carlsbad, CA). Samples were analyzed with a fluorescencemicroplate reader with filters appropriate for ~480 nm
excitation and ~520 nm emission maxima. Differences
between treatment groups were analyzed by unpaired,
two-tailed T-tests (In Stat, Sigma, St. Louis).
Dose response effects of cucurbitacin I on cerebrospinal
fluid and PDGF-BB stimulation of human leptomeningeal
and meningioma cell DNA synthesis
For analysis of effects of various doses of cucurbitacin
on cerebrospinal fluid stimulation of a grade I (M1)
meningioma were also plated in 96 well plates, serum
deprived overnight then treated with serum free DMEM,
DMEM with cerebrospinal fluid with or without cucurbita-
cin I 25, 75 or 250 nM for 72 hrs. Cells were subsequently
analyzed in 6 replicates by CyQUANT Cell Proliferation
assay (Invitrogen, Carlsbad, CA). Differences between
treatment groups were analyzed by unpaired, two-tailed
T-tests (In Stat, Sigma, St. Louis).
For analysis of effects on PDGF-BB, cells of 20wk fetal
leptomeninges, (L2) were also plated in 96 well plates,
serum deprived overnight then treated with serum free
DMEM, DMEM with recombinant human PDGF-BB
(10 ng/ml, R and D, Minneapolis, MN) with or without
cucurbitacin I 50, 100 or 200 nM for 72 hrs. Cells were
subsequently analyzed as above.
Effects of cerebrospinal fluid and cucurbitacin I on
meningioma cell JAK, STAT3, MEK1/2, p44/42MAPK, Akt,
mTOR, and Rb activation
Confluent cells from 17, 20 and 22 week primary fetal
leptomeningeal cell cultures (L1-3), 2 WHO grade I
(M2 -M 3) and 2 WHO grade II primary meningioma
cultures (M 4 and M5) were serum deprived overnight then
treated with serum free DMEM, cerebrospinal fluid without
or with 250 nM cucurbitacin I. Lysates of the cells were
then analyzed by Western blots.
For Western blots, meningioma cells were scrapped in
RIPA Lysis Buffer (Upstate Biotechnology) with 1:100 Pro-
tease Inhibitor Cocktail (Sigma) then vortexed vigorously
and frozen at –85°C. Protein concentrations were quantified
using a Bradford assay (BioRad Protein Assay reagent), then
10–35 ug protein from each was loaded on 7.5% acrylamide
gel then transferred to 0.45 um nitrocellulose membrane.
The membrane was blocked 1 hour in 5% milk in Tris-Cl
buffer with Tween 20 then reacted with an affinity puri-
fied primary antibody overnight at 4°C. This was followed
by horseradish peroxidase conjugated secondary antibody
treatment. Detection was achieved with Western Lighten-
ing (Perkin Elmer) on Xomat film (Kodak).
Western blots were analyzed with monoclonal antibodies
to STAT3, phospho-STAT3 phosphorylated at tyrosine 705,
JAK, phospho-JAK1 phosphorylated at tyrosine 1022/1023,
phosphso-MEK1/2 phosphorylated at serine 221, MAPK
44/42, phospho-MAPK 44/42 phosphorylated at threonine
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at threonine 308, phospho-mTOR phosphorylated at
serine 2448, Rb and p-Rb phosphorylated at serine 608 (all
from Cell Signaling, Beverly MA). Loading was assessed
with an antibody to actin.
Effects of cucurbitacin I on caspase 3 activation in
meningiomas
To screen for Caspase 3 activation by ARP cleavage,
near confluent cells from cultures of 2 leptomeninges
(L1 and L3) and a WHO grade I (M1) primary men-
ingioma culture were treated with serum free DMEM
with and without cucurbitacin I (250 nM) or cerebrospinal
fluid with or without cucurbitacin (250 nM). Cucurbitacin
I’s effects on apoptosis was measured by Caspase 3 ac-
tivation. Poly (ADP ribose) polymerase 1 (PARP) frag-
mentation is an indirect, semiquatitative measurement
of caspase 3 activation and apoptosis. Cleavage of the
117-kDa PARP into the 85 kDa product was assessed by
Western blot with antibody to PARP −1 (Santa Cruz,
Biotechnology, Santa Cruz, CA) and blotting procedures
detailed above.Figure 2 Effects of cucurbitacin I on cerebrospinal fluid stimulation o
from 17 (L1), 20 (L2) and 22 (L3) wk fetal leptomeninges (L), were treated w
analysis of DNA measured with a fluorescence microplate reader with filter
Changes in DNA fluorescence correlate with cell proliferation. C = control, C
***** P < 0.0005. b. Cells from WHO grade I (M1-M3) and WHO grade II (M4
**** P < 0.001, ***** P < 0.0005.Results
Effects of cucurbitacin I on cerebrospinal fluid stimulation
of meningioma cell DNA synthesis
In the leptomeningeal cells, cerebrospinal fluid significantly
stimulates DNA synthesis (p < 0.005). Co-administration of
cucurbitacin I (250 nm) produces a significant blockade
of this effect (p <0.0005). Cucurbitacin I alone also pro-
duced a significant reduction in basal DNA synthesis in L2
(p < 0.05) (Figure 2a). In WHO grade I meningiomas, cere-
brospinal fluid significantly stimulated DNA synthesis in
M1 – M3 (p < 0.001). Co-administration of cucurbitacin I
(250 nm) blocked this effect (p < 0.0005). In M2, cucurbita-
cin I alone also significantly reduced basal synthesis (p <
0.005). In WHO grade II meningiomas, cerebrospinal fluid
significantly stimulated DNA synthesis in M4 and M5 (p <
0.001). Co-administration of cucurbitacin (250 nM) signifi-
cantly blocked this effect (p < 0.0005). In M5, cucurbitacin
reduced basal DNA synthesis (p < 0.05) (Figure 2b).
Cucurbitacin I also produced a dose dependent reduction
in cerebrospinal fluid stimulation in a grade I meningioma
(M2) and l grade 2 (M6). Cucurbitacin I (25 nM) had no
effect on cerebrospinal fluid stimulation of DNA synthesisf leptomeningeal and meningioma cell DNA synthesis. a. Cells
ith CSF without or with cucurbitacin I (250 nM) for 72 hrs. CyQUANT
s appropriate for ~480 nm excitation and ~520 nm emission maxima.
SF = cerebrospinal fluid. * P < 0.05, *** P < 0.005, **** P < 0.001,
-M5) meningiomas were treated as above. * P < 0.05, *** P < 0.005,
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lation (Figure 3b).
Effects of cucurbitacin on PDGF-BB stimulation of human
leptomeningeal and meningioma cell DNA synthesis
In L2, cucurbitacin I produced a dose dependent reduction
in PDGF-BB stimulated DNA synthesis at 50 nM (p = 0.005)
100 nM (p = 0.01) and 200 nM (p = 0.01) doses (Figure 3a).
Effects of cerebrospinal fluid and cucurbitacin I on
meningioma cell JAK, STAT3, MEK1/2, p44/42MAPK, Akt,
mTOR, and Rb activation
Cerebrospinal fluid had no effect on JAK1 phosphorylation
in any of the meningioma cells studies (M2-M6) but
stimulated STAT3 phosphorylation in all 3 leptomeningeal
cultures and meningioma cells M1, M3–M6. Cucurbi-
tacin I decreased STAT3 phosphorylation in L1-L3.Figure 3 Cucurbitacin I dose response curves. a. Effects of cucurbitacin
synthesis. Fetal leptomeningeal cells (L2) were treated with PDGF-BB witho
analysis of DNA measured by fluorescence at 480/520 nm. Changes in DNA
growth factor-BB. * P < 0.05, *** P < 0.005, ***** P < 0.001. b. Effects of cucu
synthesis. WHO grade I (M2) and grade II (M6) meningioma cells were trea
for 72 hrs. CyQUANT analysis of DNA measured by fluorescence at 480/520
CSF = cerebrospinal fluid * P < 0.05, *** P < 0.005, **** P < 0.001, ***** P < 0.Co-administration of cerebrospinal fluid and cucurbitacin
I decreased phosphorylation in M5. In M4 an increase was
seen with co-administration. Cerebrospinal fluid reduced
MEK1/2 phosphorylation in M2, M4-M6. Cerebrospinal
fluid with and without cucurbitacin I was also associated
with a reduction of MEK1/2 phosphorylation in M2,
M4-M6. Cerebrospinal fluid with or without cucurbitacin I
also decreased p44/42MAPK phosphorylation in L2,
M4-M6 (Figure 4 and data not shown). Cerebrospinal
fluid increased Akt phosphorylation in M6. Cucurbita-
cin I alone and with cerebrospinal fluid had no effect
on Akt phosphorylation in M3, 5 and 6. Cerebrospinal
fluid, curbitacin I with or without cerebrospinal fluid
had no effect on mTOR phosphorylation in M2-M6.
Neither cerebrospinal fluid nor cucurbitacin 1 with or
without cerebrospinal fluid had an effect on Rb phosphor-
ylation (Figure 4 and data and not shown).I on PDGF-BB stimulation of human leptomeningeal cell DNA
ut or with cucurbitacin I (50, 100 or 200 nM) for 72 hrs. CyQUANT
fluorescence correlate with cell proliferation. PDGF = Platelet derived
rbitacin on cerebrospinal fluid stimulation of meningioma cell DNA
ted with CSF without or with cucurbitacin (25 nM, 75 nM or 250 nM)
nm. Changes in DNA fluorescence correlate with cell proliferation.
0005.
Figure 4 Western blot analysis of effects of cucurbitacin I on phosphorylation/activation of signaling pathways in human leptomeningeal
and meningioma cells. a. Effects of cucurbitacin I on phosphorylation/activation of STAT3, and p44/42MAPK in human leptomeningeal cells.
Leptomeningeal cells from 17 (L1) and 20 wk (L2) were treated with serum free media (C), cerebrospinal fluid (CF) without or with
cucurbitacin I (Cu) (250 nM) for 72 hrs. Cerebrospinal fluid stimulated STAT3 phosphorylation. Cucurbitacin I had no effect on basal STAT3
phosphorylation but co-administration with cerebrospinal fluid blocked cerebrospinal fluid stimulation of STAT3 phosphorylation in each.
b. Effects of cucurbitacin I on phosphorylation/activation of JAK, STAT3, pMEK1/2, p44/42MAPK and mTOR in meningioma cells. WHO grade
I (M2 and 3) and (B) WHO grade II (M4 and 5) meningiomas were treated with serum free media (C), cerebrospinal fluid (CF) without or with
cucurbitacin I (Cu) (250 nM) for 72 hrs. In the grade I meningiomas, cerebrospinal fluid stimulated phosphorylation of STAT3 and decreased
it in MEK1/2. Cucurbitacin I had no effect. In the grade II meningiomas, cerebrospinal fluid stimulated STAT3 phosphorylation in all and
reduced phosphorylation of MEK1/2 in all and p44/42MAPK in one. Cucurbitacin reduced basal p44/42 MAPK phosphorylation.
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Western blots reveal intact native 117 kDa PARP in all
of the treatment groups. Cucurbitacin I had no effect on
activation of caspase 3 in the L1 and L3 leptomeninges
or grade I M1 meningioma cells. Cerebrospinal fluid
increased the approximately 78 KDa cleavage product
in L3 and M1 (data not shown).
Discussion
In the present study, curcubitacin I blocked cerebrospinal
fluid stimulation of leptomeningeal, WHO grade I and
II cell proliferation in each of the primary cell cultures.
These findings suggest that cucurbitacin may be useful
in treatment of select meningiomas. Cucurbitacin I ap-
pears to be a potent inhibitor in meningioma cells and
effective at concentrations similar to that effective on
nasopharyngeal carcinoma cells [30] and lower than ef-
fective on ALK-positive anaplastic large cell lymphoma
cells [32] and pancreatic carcinoma cells [29].
In previous studies cucurbitacin selectively inhibited phos-
phorylation of STAT3 but not ERK 1 or 2 (P44/42 MAPK),
JNK-1 or AKT in NIH 3 T3 cells and adenocarcinoma
cell lines [26]. Nonetheless, our findings suggest the
mechanisms underlying cucurbitacins antiproliferativeeffects on meningioma cells are more complex. In the
leptomeninges and one meningioma, cucrbitacin I’s effects
correlated with reduced phosphorylation of STAT3. In
one grade II meningioma, co-administration of cere-
brospinal fluid and cucurbitacin I appeared to increase
STAT3 phosphorylation (M4) but this was in a case
showing particularly robust proliferation in response
to cerebrospinal fluid which might be harder to block.
The meningioma cells also, in some instances, reduced
phosphorylation of p44/42MAPK. While p44/42MAPK
regulates numerous cellular functions, the findings raise
the possibility that it might also participate in cucurbitacin
I’s antiproliferative effects in some cells and doses.
Previously we have found that STAT3 phosphorylation/
activation was associated with cerebrospinal fluid stimula-
tion of irradiated leptomeningeal cell [39] and meningioma
cell proliferation [22,23]. It is also important in meningioma
progression to a higher grade [21,40,41]. Cucurbitacin I’s
effect on STAT3 appears to be at the level of STAT3 since
it had no effect on upstream components of pathways that
activate STAT3 particularly JAK1. Cucurbitacin I appears
to reduce the level of tyrosine phosphorylation on STAT3
reducing phospho-STAT3 binding to transcription factors
[26]. Nonetheless, cucurbitacin I also reduced levels of
p44/42MAPK phosphorylation in the leptomeninges,
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others have found p44/42MAPK activation important
to meningioma cell proliferation [19,42]. Cucurbitacin
also blocked PDGF-BB stimulation of leptomeningeal cell
proliferation. PDGF-BB activates STAT3 in some cells and
also p44/42 MAPK in leptomeningeal cells consequently
cucurbitacin I’s effects could reflect inhibition of STAT3
alone or with p44/42 MAPK.
STAT3 is one of a family of proteins with a phosphotyr-
osine and DNA binding domain that acts as a transcrip-
tion factor [43-47]. Latent STAT3 is activated by a several
growth factor/cytokine receptors that phosphorylate JAK1
in receptor complexes or STAT3 independently resulting
in latent cytoplasmic STAT dimerization and transloca-
tion into the nucleus where it increases transcription
factors promoting cell proliferation [43-46]. Of interest,
recombinant IL-6 treatment reportedly had no effect or was
inhibitory to WHO grade I meningioma cell proliferation
in vitro [21]. Moreover, cerebrospinal fluid activation/
phosphorylation of STAT3, at least in human leptomenin-
geal and meningioma cells, appears to be independent of an
IL-6 receptor-JAK-STAT3 pathway [23]. Thus STAT3 acti-
vation may be via several cytokine/growth factor receptor/
kinases [41] and/or by the MEK-1-MAPK and PI3k-Akt-
mTOR pathways [44-47] that we and others have found
to be mitogenic to meningioma cells [19,20,42].
Cucurbitacin I effects on meningioma cell apoptosis are
uncertain. Curcubitacin I had no detectable effect on cleav-
age of PARP, a marker of caspase 3 activity. Nonetheless,
due to the limitations inherent to using primary cultures
and limited amounts of cerebrospinal fluid from patients
without neurological disease, our analysis was limited in
scope and time points analyzed. In another study, in com-
bination with gemcitabine, cucurbitacin increased PARP
cleavage in pancreactic carcinoma cells [29].
Cerebrospinal fluid from multiple different patients stim-
ulated leptomeningeal and meningioma cell proliferation.
These findings extend our previous observations that cere-
brospinal fluid from a numerous different adults of various
ages and both genders has the potential to stimulate lepto-
meningeal or meningioma cell proliferation under some cir-
cumstances in vivo and may participate in the pathogenesis
of meningiomas [23]. For example, recently we have found
that prior irradiation, a known initiator of meningioma for-
mation, may sensitize leptomeningeal cells to the mitogenic
effects of cerebrospinal fluid in some scenarios [39]. These
findings underscore the need to clarify the effects of cere-
brospinal fluid on meningioma growth and identify chemo-
therapies that may block any mitogenic effects in vivo.
Conclusions
Cucurbitacin I is a potent inhibitor of meningeal and
meningioma cell proliferation that warrants further
study as a nonsurgical alternative therapy for meningiomas.While its mechanism of action may be primarily thru
inhibition of STAT3 phosphorylation/activation, other
mechanisms may contribute to its growth inhibitory effects.
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